Literature DB >> 18958847

Nanoparticle formulations in pulmonary drug delivery.

Mark M Bailey1, Cory J Berkland.   

Abstract

The advent of nanotechnology has reignited interest in the lungs as a major route of drug delivery for both systemic and local treatments. The large surface area of the lungs and the minimal barriers impeding access to the lung periphery make this organ a suitable portal for a variety of therapeutic interventions. Nanoparticles provide new formulation options for both dispersed liquid droplet dosage forms such as metered dose inhalers and nebulizers, and dry powder formulations. Nanoparticle formulations have many advantages over traditional dosage forms, such as enhanced dissolution properties and the potential for intracellular drug delivery. Specifically, pure drug nanoparticles, polymeric nanoparticles, polyelectrolyte complexes, and drug-loaded liposomes offer some encouraging results for delivering drugs to and through the lungs. Methods are also being investigated to produce nanoparticles with properties suitable for improving access to the peripheral lung. Traditional techniques such as spray drying and grinding, and more recent advances in supercritical fluid extraction, precipitation, and solvent extraction have been employed to produce nanoparticle formulations for pulmonary delivery. Here, the benefits of nanoparticle formulations and current progress are compared in light of the practical encumbrances of producing formulations, and possible toxicological effects of these materials. (c) 2008 Wiley Periodicals, Inc.

Mesh:

Substances:

Year:  2009        PMID: 18958847     DOI: 10.1002/med.20140

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  46 in total

Review 1.  Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery.

Authors:  Lauren Willis; Don Hayes; Heidi M Mansour
Journal:  Lung       Date:  2012-01-25       Impact factor: 2.584

2.  Self-associated submicron IgG1 particles for pulmonary delivery: effects of non-ionic surfactants on size, shape, stability, and aerosol performance.

Authors:  Asha R Srinivasan; Sunday A Shoyele
Journal:  AAPS PharmSciTech       Date:  2012-12-20       Impact factor: 3.246

Review 3.  Nanocarriers targeting dendritic cells for pulmonary vaccine delivery.

Authors:  Nitesh K Kunda; Satyanarayana Somavarapu; Stephen B Gordon; Gillian A Hutcheon; Imran Y Saleem
Journal:  Pharm Res       Date:  2012-10-09       Impact factor: 4.200

Review 4.  Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling.

Authors:  Darren Michael Moss; Marco Siccardi
Journal:  Br J Pharmacol       Date:  2014-07-02       Impact factor: 8.739

5.  Physicochemical characterization of nebulized superparamagnetic iron oxide nanoparticles (SPIONs).

Authors:  Halshka Graczyk; Louise C Bryan; Nastassja Lewinski; Guillaume Suarez; Geraldine Coullerez; Paul Bowen; Michael Riediker
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2014-05-06       Impact factor: 2.849

Review 6.  In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles.

Authors:  Hamed Arami; Amit Khandhar; Denny Liggitt; Kannan M Krishnan
Journal:  Chem Soc Rev       Date:  2015-09-21       Impact factor: 54.564

7.  Preparation of 5-fluorouracil nanoparticles by supercritical antisolvents for pulmonary delivery.

Authors:  Pardis Kalantarian; Abdolhosein Rouholamini Najafabadi; Ismaeil Haririan; Alireza Vatanara; Yadollah Yamini; Majid Darabi; Kambiz Gilani
Journal:  Int J Nanomedicine       Date:  2010-10-05

8.  Influence of suspension stabilisers on the delivery of protein-loaded porous poly (DL-lactide-co-glycolide) (PLGA) microparticles via pressurised metered dose inhaler (pMDI).

Authors:  Elizabeth Cocks; Satyanarayana Somavarapu; Oya Alpar; David Greenleaf
Journal:  Pharm Res       Date:  2014-02-19       Impact factor: 4.200

9.  Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension.

Authors:  Vivek Gupta; Nilesh Gupta; Imam H Shaik; Reza Mehvar; Ivan F McMurtry; Masahiko Oka; Eva Nozik-Grayck; Masanobu Komatsu; Fakhrul Ahsan
Journal:  J Control Release       Date:  2013-01-23       Impact factor: 9.776

Review 10.  Nanomedicine in pulmonary delivery.

Authors:  Heidi M Mansour; Yun-Seok Rhee; Xiao Wu
Journal:  Int J Nanomedicine       Date:  2009-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.